InMed Pharmaceuticals (INM) Other Non Operating Income (2019 - 2026)
InMed Pharmaceuticals (INM) reported Other Non Operating Income of -$23168.0 for Q1 2026, down 4.53% on a YoY basis from -$24266.1 in Q1 2025, and down 227.75% quarter-over-quarter from $18136.0 in Q4 2025.
InMed Pharmaceuticals (INM) Other Non Operating Income (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Other Non Operating Income for 8 years, with the latest figure at -$23168.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income fell 4.53% year-over-year to -$23168.0; the trailing twelve-month figure through Mar 2026 stood at -$39889.0 (up 47.38% YoY), and the FY2025 full-year result was -$28471.0, up 54.02% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$23168.0, down from $18136.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $59896.0 in Q4 2023, with the low at -$96791.0 in Q3 2022.
- Historically, Other Non Operating Income has averaged -$13943.5 across 5 years, with a median of -$22165.0 in 2025.
- Annual changes were most pronounced in 2022 — Other Non Operating Income soared 573.0% — and 2024, when it sank 1662.02%.
- InMed Pharmaceuticals' Other Non Operating Income stood at $20237.0 in 2022, then jumped by 195.97% to $59896.0 in 2023, then slumped by 179.73% to -$47753.0 in 2024, then jumped by 137.98% to $18136.0 in 2025, then slumped by 227.75% to -$23168.0 in 2026.
- The last three Other Non Operating Income figures came in at -$23168.0 (Q1 2026), $18136.0 (Q4 2025), and -$56994.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn |
| 10 | InMed Pharmaceuticals | 6.00 Mn | 756,271.05 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23,168.00 |
| Dec 31, 2025 | 18,136.00 |
| Sep 30, 2025 | -56,994.00 |
| Jun 30, 2025 | 22,137.00 |
| Mar 31, 2025 | -22,165.00 |
| Dec 31, 2024 | -47,753.00 |
| Sep 30, 2024 | 19,310.00 |
| Jun 30, 2024 | -25,204.00 |
| Mar 31, 2024 | -48,156.00 |
| Dec 31, 2023 | 59,896.00 |
| Sep 30, 2023 | -48,457.00 |
| Jun 30, 2023 | 31,112.00 |
| Mar 31, 2023 | -2,733.00 |
| Dec 31, 2022 | 20,237.00 |
| Sep 30, 2022 | -96,791.00 |
| Jun 30, 2022 | -69,442.00 |
| Mar 31, 2022 | 32,996.00 |
| Dec 31, 2021 | 3,007.00 |
| Sep 30, 2021 | -84,112.00 |
| Jun 30, 2021 | -405,729.00 |